Navigation Links
BioPharmX Presents Poster at American Academy of Dermatology Annual Meeting Suggesting BPX-01 Safely, Efficiently Delivers Acne-Fighting Minocycline to Pilosebaceous Units

MENLO PARK, Calif., March 2, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will share early clinical and pre-clinical data at the 2017 American Academy of Dermatology (AAD) Annual Meeting, which will show the company's novel topical gel BPX-01 may deliver acne-fighting medication to a target area without side effects.

A poster sharing the research, titled "Development and Assessment of BPX-01, a Novel Topical Minocycline Gel for Treatment of Acne Vulgaris," will be available for viewing at the event March 3-6. In addition, BioPharmX Senior Director of Preclinical Drug Development Usha Nagavarapu will deliver a presentation based on the poster on March 3 at 10:10 a.m. The AAD meeting, being held in Orlando, Fla., is one of the world's largest gatherings of dermatologists.

Continue Reading
BioPharmX (BPMX) (PRNewsFoto/BioPharmX Corporation) (PRNewsFoto/BioPharmX Corporation)
BioPharmX (BPMX) (PRNewsFoto/BioPharmX Corporation) (PRNewsFoto/BioPharmX Corporation)

Oral minocycline is routinely prescribed for the treatment of acne, but because the drug is delivered systemically, undesirable side effects, such as upset stomach, diarrhea, dizziness and headache often result. BPX-01 is the first topical gel formulation of minocycline, which may enable the use of a much lower dosage of drug, and which clinical and pre-clinical studies suggest thus far does not enter the blood system in measurable quantities.

"The 'Holy Grail' in acne treatment is optimizing both efficacy and tolerability," said Dr. Ted Lain, board certified dermatologist and investigator on the BioPharmX Phase 2b study of BPX-01. "What dermatologists desperately need is a product with both a very limited side effect profile and reliable efficacy comparable to that of oral antibiotics."

BPX-01[1] is the first and only stable hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit. The company's studies are designed to confirm whether BPX-01 can effectively treat acne with lower, and potentially safer, dosages of the antibiotic.

"The research to date shows that BPX-01 topical gel may effectively and safely deliver minocycline to target areas," said Kin F. Chan, executive vice president of research and technology at BioPharmX. "The studies so far offer promise to millions of people who cannot take oral minocycline to treat their acne, including the many individuals who are intolerant of systemic antibiotic treatments."

BioPharmX is currently conducting an OPAL (tOPicAL Minocycline Gel) study – a Phase 2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, double-blind, three-arm, vehicle-controlled study involves 225 individuals, aged 9 to 40, who have moderate-to-severe inflammatory, non-nodular acne vulgaris.

The AAD calls acne the "most common skin condition in the United States," affecting 40 million to 50 million Americans. The U.S. market for prescription acne medications is estimated at $4 billion. 

About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women's health. To learn more about BioPharmX, visit

Forward-Looking Statement
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, whether BPX-01 will deliver acne-fighting medication to a target area without side effects, whether BPX-01 will enable the use of a much lower dosage of minocycline, whether topical minocycline enters the blood system in measurable quantities, and whether BPX-01 can effectively treat acne with lower, and potentially safer, dosages of the antibiotic. These forward-looking statements may be identified by words such as "may", "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

BioPharmX is a registered trademark of BioPharmX, Inc.

[1] Caution: BPX-01 is a new drug limited by federal or U.S. law to investigational use.


To view the original version on PR Newswire, visit:

SOURCE BioPharmX Corporation
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Biotech Stocks Under Scanner -- Kite Pharma, BioPharmX, OvaScience, and Regeneron Pharma
2. BioPharmX Data Suggest Anti-Inflammatory Activity of BPX-01 Topical Minocycline Gel
3. BioPharmX Corporation Announces Closing of a $12.5 Million Unit Offering
4. Study Shows Topical BioPharmX Formulation Treats Acne While Minimizing Systemic Exposure of Minocycline
5. BioPharmX Corporation Reports Third Quarter Financial Results
6. BioPharmX Corporation to Report Third Quarter Financial Results on December 14, 2015
7. Study Shows Safety of BioPharmX Topical Formulation
8. BioPharmX Corporation Closes Direct Investment
9. Study Shows BioPharmX Formulation Offers More Effective Acne Treatment by Targeted Delivery of Minocycline
10. Study Shows Novel BioPharmX Formulation Promises Breakthrough in Acne Treatment
11. BioPharmX Corporation Expands Management Team to Support Growth and Market Expansion
Post Your Comments:
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):